Retrieve available abstracts of 333 articles: HTML format
Single Articles
June 2025
FUKUDA K, Nanjo S, Takeuchi S, Chakrabarti T, et al Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in
EGFR-mutant lung cancer.
J Thorac Oncol. 2025 Jun 13:S1556-0864(25)00766. PubMedAbstract available
PETERS S, Regan MM, Paz-Ares LG, Reck M, et al Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic
Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab
Versus Chemotherapy in CheckMate 227 Part 1.
J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00749. PubMedAbstract available
MASCAUX C, Sen T, Sanchez-Cespedes M, Ortiz-Cuaran S, et al Advances in lung cancer basic and translational research in 2025 - Overview and
perspectives focusing on non-small cell lung cancer.
J Thorac Oncol. 2025 Jun 3:S1556-0864(25)00754. PubMedAbstract available
TAMMEMAGI MC, Borondy-Kitts A, Field JF, Mohan A, et al A Response to the Letter to the Editor: "Quality Performance Indicators for Lung
Cancer Screening: Towards the Next Levels?".
J Thorac Oncol. 2025;20:e69-e71. PubMed
MEERBEECK JV, Hal GV, Snoeckx A Quality Performance Indicators for Lung Cancer Screening: Towards the Next
Levels?
J Thorac Oncol. 2025;20:e68-e69. PubMed
REVEL MP Overcoming Barriers to Lung Cancer Screening: The Incidental Pulmonary Nodule
Strategy.
J Thorac Oncol. 2025;20:705-707. PubMed
FU F, Chen H Bridging the Gap in Surgery for Octogenarians With Early-Stage Lung Cancer.
J Thorac Oncol. 2025;20:703-704. PubMed
SCHEFFLER M, Wolf J, Michels S Can Immunotherapy Be Omitted in KRAS G12C-Mutant Lung Cancer by 2025?
J Thorac Oncol. 2025;20:692-694. PubMed
SPIRA AI, Paz-Ares L, Han JY, Shih JY, et al Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From
SKIPPirr, a Phase 2 Study: A Brief Report.
J Thorac Oncol. 2025;20:809-816. PubMedAbstract available
MAO S, Liu X, Wang L, Wang Y, et al AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase
Inhibitor Resistance in NSCLC.
J Thorac Oncol. 2025;20:739-749. PubMedAbstract available
May 2025
CHADDHA U, Agrawal A, Ghori U, Kheir F, et al Safety and Sample Adequacy for Comprehensive Biomarker Testing of Bronchoscopic
Biopsies: An American Association of Bronchology and Interventional Pulmonology
(AABIP) and International Association for the Study of Lung Cancer (IASLC)
Clinical Practic
J Thorac Oncol. 2025 May 24:S1556-0864(25)00722. PubMedAbstract available
HERBST RS, Cho BC, Zhou C, Burotto M, et al Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy
for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: Phase 3 LEAP-006 Study.
J Thorac Oncol. 2025 May 24:S1556-0864(25)00724. PubMedAbstract available
KREBS MG, Cho BC, Hiret S, Han JY, et al Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and
MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.
J Thorac Oncol. 2025 May 16:S1556-0864(25)00720. PubMedAbstract available
RODE MM, Sykes AG, Allen MS, Ingalls LA, et al Risk-Based Lung Cancer Screening in Clinical Practice.
J Thorac Oncol. 2025 May 14:S1556-0864(25)00717. PubMedAbstract available
JONES SB, Chan C, Filippi AR, Harada K, et al Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable
Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International
Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology
(ART) Subcommi
J Thorac Oncol. 2025 May 9:S1556-0864(25)00710. PubMedAbstract available
WIESWEG M, Alaffas A, Rasokat A, Saalfeld FC, et al Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line
targeted therapy versus first-line (chemo-) immunotherapy.
J Thorac Oncol. 2025 May 7:S1556-0864(25)00706. PubMedAbstract available
SABARI JK, Yu HA, Mahadevia PJ, Liu Y, et al Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with
First-line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in
the United States.
J Thorac Oncol. 2025 May 2:S1556-0864(25)00699. PubMedAbstract available
BOSTOCK I, Fox A, Engelhart K, Farjah F, et al Response to Letter to the Editor: "Refining Surgical Decision-Making for Elderly
With Lung Cancer Patients: Recognized Risks, Unmet Needs".
J Thorac Oncol. 2025;20:e63-e64. PubMed
WANG F, Bao M, Zhu L Refining Surgical Decision-Making for Elderly Patients With Lung Cancer:
Recognized Risks, Unmet Needs.
J Thorac Oncol. 2025;20:e62-e63. PubMed
MREMI A, Ndumbalo J, Chuwa H, Henke O, et al Lung Cancer in Tanzania.
J Thorac Oncol. 2025;20:560-564. PubMed
DE-TORRES JP, Varo N The Tree That Let Us See the Forest: The Importance of Comorbidities in Lung
Cancer Screening Programs.
J Thorac Oncol. 2025;20:555-556. PubMed
YANAGISAWA A, Shiroyama T, Miyake K, Takeda Y, et al Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report.
J Thorac Oncol. 2025;20:676-679. PubMedAbstract available
LINDBERG A, Muhl L, Yu H, Hellberg L, et al In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand
1 Interactions as a Functional Predictor for Response to Immune Checkpoint
Inhibition in NSCLC.
J Thorac Oncol. 2025;20:625-640. PubMedAbstract available
April 2025
GRONBERG BH, Killingberg KT, Flotten O, Bjaanaes MM, et al High-dose versus standard dose twice-daily thoracic radiotherapy in limited stage
small-cell lung cancer: final survival data, long-term toxicity and relapse
patterns in a randomised, open-label, phase II trial.
J Thorac Oncol. 2025 Apr 19:S1556-0864(25)00696. PubMedAbstract available
GULDBRANDSEN KF, Bloch M, Skougaard K, Ahlborn LB, et al Surveillance with [(18)F]FDG PET/CT of stage I-III lung cancer patients after
completion of curative treatment (SUPE_R): a randomized controlled trial.
J Thorac Oncol. 2025 Apr 19:S1556-0864(25)00693. PubMedAbstract available
HAMADA A, Soh J, Hata A, Nakamatsu K, et al Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and
Adjuvant Immunotherapy for Resectable Stage III N2 Non-Small Cell Lung Cancer:
Primary Results from SQUAT trial (WJOG 12119L).
J Thorac Oncol. 2025 Apr 9:S1556-0864(25)00656. PubMedAbstract available
BOERI M, Zanghi A, Pastorino U New Horizons in Lung Cancer Screening: Eligibility Criteria, Risk Models, and
Emerging Challenges.
J Thorac Oncol. 2025;20:422-424. PubMed
KIM YW, Lee CT Advancing the Implementation of Risk Model-Based Lung Cancer Screening.
J Thorac Oncol. 2025;20:419-421. PubMed
PARIKH K, Hashmi A, Chauhan PS, Chaudhuri AA, et al Plasma-First Testing in Advanced Lung Cancer: Evidence and Implications.
J Thorac Oncol. 2025;20:411-414. PubMed
XIA Y, Wang K, Zhao J, Arter Z, et al Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant
NSCLC: A Multi-Center Analysis and Literature Review.
J Thorac Oncol. 2025;20:465-474. PubMedAbstract available
NAKAGAWA K, Garon EB, Seto T, Nishio M, et al RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in
Untreated, EGFR-Mutated Metastatic NSCLC.
J Thorac Oncol. 2025;20:487-499. PubMedAbstract available
BLECHTER B, Hsiung CA, Wang X, Zhang H, et al Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR
Mutation Status: A Brief Report.
J Thorac Oncol. 2025;20:521-530. PubMedAbstract available
LEUNISSEN DJG, Moonen L, von der Thusen JH, den Bakker MA, et al Identification of Defined Molecular Subgroups on the Basis of Immunohistochemical
Analyses and Potential Therapeutic Vulnerabilities of Pulmonary Carcinoids.
J Thorac Oncol. 2025;20:451-464. PubMedAbstract available
March 2025
SEDER CW, Chang SC, Towe CW, Puri V, et al Anatomic Lung Resection is Associated with Improved Survival Compared with Wedge
Resection for Stage IA (=2 cm) Non-Small Cell Lung Cancer.
J Thorac Oncol. 2025 Mar 23:S1556-0864(25)00641. PubMedAbstract available
HAKOZAKI T, Tanaka K, Shiraishi Y, Sekino Y, et al Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving
Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial
JCOG2007 (NIPPON).
J Thorac Oncol. 2025 Mar 7:S1556-0864(25)00106. PubMedAbstract available
CHEN P, Wang H, Tang Z, Shi J, et al Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic
T cells in lung cancer via dendritic cells.
J Thorac Oncol. 2025 Mar 6:S1556-0864(25)00109. PubMedAbstract available
BROWN M, Myers R, Lam S Enlarging the Reach of Screening and Early Detection of Lung Cancer.
J Thorac Oncol. 2025;20:249-251. PubMed
CHOU TY, Dacic S, Wistuba I, Beasley MB, et al Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary
Metastases With Emphasis on Pathological and Molecular Considerations:
Recommendations From the International Association for the Study of Lung Cancer
Pathology Committee.
J Thorac Oncol. 2025;20:311-330. PubMedAbstract available
LU S, Wu L, Wang Q, Wang Z, et al Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With
Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3
PEARL Study.
J Thorac Oncol. 2025;20:366-382. PubMedAbstract available
MARINELLI D, Nuccio A, Di Federico A, Ambrosi F, et al Improved Event-Free Survival After Complete or Major Pathologic Response in
Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy
Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data
Meta-Analysis.
J Thorac Oncol. 2025;20:285-295. PubMedAbstract available
February 2025
XIE D, Zhang L, He N, Yang C, et al Overdiagnosis of Lung Cancer due to Introduction of Low-Dose Computed Tomography
in Average-Risk Populations in China.
J Thorac Oncol. 2025 Feb 13:S1556-0864(25)00072. PubMedAbstract available
CALLES A, Navarro A, Doger Speville Uribe BG, Alvarez Colome E, et al Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the
phase I/II LUPER study.
J Thorac Oncol. 2025 Feb 10:S1556-0864(25)00064. PubMedAbstract available
FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al Corrigendum to 'The International Association for the Study of Lung Cancer
Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors
in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer'
[Journal of Thoraci
J Thorac Oncol. 2025 Feb 9:S1556-0864(25)00050. PubMed
HAN B, Liu J, Wu L, Zhao Y, et al Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib
Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1
Dose-Escalation and Dose-Expansion Study.
J Thorac Oncol. 2025 Feb 8:S1556-0864(25)00062. PubMedAbstract available
LI YS, Yu Q, Bu Q, Lin L, et al First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without
Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003
Randomized Placebo-Controlled Trial.
J Thorac Oncol. 2025 Feb 8:S1556-0864(25)00063. PubMedAbstract available
ABBAR B, Labreche K, Cadranel J, Veyri M, et al HIV Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational
Profiles in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2025 Feb 7:S1556-0864(25)00060. PubMedAbstract available
SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al A Response to the Letter to the Editor: "Failure to Include Nonsmokers in
Computed Tomography Screening for Lung Cancer is Unjust".
J Thorac Oncol. 2025;20:e39-e40. PubMed
SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al A Response to the Letter to the Editor: "Lung Cancer Screening in Low-Risk
Populations: Ethical Considerations, Technological Advancements, and
Socioeconomic Challenges".
J Thorac Oncol. 2025;20:e36-e37. PubMed
LI J, Zhang Y, Fu T, Tong Y, et al Lung Cancer Screening in Low-Risk Populations: Ethical Considerations,
Technological Advancements, and Socioeconomic Challenges.
J Thorac Oncol. 2025;20:e35-e36. PubMed
SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al A Response to the Letter to the Editor: "Secondhand Smoke in Low-Risk Groups: A
Hidden Danger in Lung Cancer Screening".
J Thorac Oncol. 2025;20:e34. PubMed
CUI Y Secondhand Smoke in Low-Risk Groups: A Hidden Danger in Lung Cancer Screening.
J Thorac Oncol. 2025;20:e33-e34. PubMed
RIZZO MM, Barros M, Chimondeguy D, Dalurzo ML, et al Lung Cancer in Argentina.
J Thorac Oncol. 2025;20:144-149. PubMed
BAK M, Park H, Lee SH, Lee N, et al The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World
Population.
J Thorac Oncol. 2025;20:167-176. PubMedAbstract available
NAKAGAWA K, Watanabe SI, Wakabayashi M, Yotsukura M, et al Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis
of the JCOG0802/WJOG4607L Trial.
J Thorac Oncol. 2025;20:157-166. PubMedAbstract available
LEE J, Jeon JH, Chung JH, Son JW, et al Prognostic Impact of Non-Predominant Lepidic Components in Pathologic Stage I
Invasive Nonmucinous Adenocarcinoma.
J Thorac Oncol. 2025;20:194-202. PubMedAbstract available
January 2025
LIAO W, Ray MA, Patel A, Roma J, et al Barriers to Lung Cancer Screening in a Multi-Disciplinary Thoracic Oncology
Program Cohort: Effects of an Incidental Pulmonary Nodule Program.
J Thorac Oncol. 2025 Jan 30:S1556-0864(25)00057. PubMedAbstract available
BOSTOCK IC, Fox AH, Ward RC, Engelhardt KE, et al Outcomes After Surgical Management of Early-Stage Lung Cancer in Octogenarians:
An in-depth Analysis of a Nationally Representative Cohort.
J Thorac Oncol. 2025 Jan 28:S1556-0864(25)00053. PubMedAbstract available
TAMMEMAGI MC, Borondy-Kitts A, Field JK, Henschke CI, et al Lung cancer screening program quality indicators - review & recommendations - An
International Association for the Study of Lung Cancer Delphi process study.
J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00052. PubMedAbstract available
GANDHI MM, Elkrief A, Moore CG, Ricciuti B, et al Gene copy deletion of STK11, KEAP1, and SMARCA4: clinicopathologic features and
association with outcomes to immunotherapy +/- chemotherapy in nonsquamous
non-small cell lung cancer.
J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00049. PubMedAbstract available
TSAO MS, Rosenthal A, Nicholson AG, Detterbeck F, et al The International Association for the Study of Lung Cancer Staging Project: The
Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine
Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung
Cancer.
J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00046. PubMedAbstract available
AKAMATSU H, Sakata S, Azuma K, Yoshioka H, et al A single-arm, phase II study of sotorasib plus carboplatin/pemetrexed in advanced
non-squamous non-small cell lung cancer patients with KRAS G12C mutation
(WJOG14821L, SCARLET).
J Thorac Oncol. 2025 Jan 17:S1556-0864(25)00007. PubMedAbstract available
GENDARME S, Irajizad E, Long JP, Fahrmann JF, et al Impact of comorbidities on the mortality benefits of lung cancer screening: a
post-hoc analysis of PLCO and NLST trials.
J Thorac Oncol. 2025 Jan 9:S1556-0864(25)00004. PubMedAbstract available
BESSE B, Goto K, Wang Y, Lee SH, et al Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung
Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy:
Results From CHRYSALIS-2 Cohort A.
J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02550. PubMedAbstract available
FUKUI T, Mamesaya N, Takahashi T, Kishi K, et al A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR
Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status
(OPEN/TORG2040).
J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02548. PubMedAbstract available
DOWLATI A, Chiang AC, Cervantes A, Babu S, et al Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in
Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03.
J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02549. PubMedAbstract available
HUBER RM, Lam S, Cavic M, Balata H, et al Response to the Letters to the Editor by Jing Peng and Colleagues and by Lauren C
Leiman Regarding the Manuscript "Terminology Issues in Screening and Early
Detection of Lung Cancer-International Association for the Study of Lung Cancer
Early Detectio
J Thorac Oncol. 2025;20:e6-e8. PubMed
PENG J, Zhao L, Shan D Enhancing Clinical Precision and Patient Communication in Lung Cancer Screening.
J Thorac Oncol. 2025;20:e3-e4. PubMed
GADGEEL SM, Jensen E, Shamoun M, Rajagopalan K, et al Response to: Enhancing Clinical Practice: Critical Insights for Medical Workers
in Applying Pembrolizumab for Metastatic NSCLC and Pembrolizumab, Chemotherapy
and Metastatic Non-Small Cell Lung Cancer.
J Thorac Oncol. 2025;20:e11-e12. PubMed
BORGHAEI H, Mok T Leptomeningeal Disease in Lung Cancer: An Unmet Need That Needs to Be Met.
J Thorac Oncol. 2025;20:17-19. PubMed
LI HJ, Qiu ZB, Wang MM, Zhang C, et al Radiomics-Based Support Vector Machine Distinguishes Molecular Events Driving the
Progression of Lung Adenocarcinoma.
J Thorac Oncol. 2025;20:52-64. PubMedAbstract available
PETERS S, Cho BC, Luft AV, Alatorre-Alexander J, et al Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in
First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3
POSEIDON Trial.
J Thorac Oncol. 2025;20:76-93. PubMedAbstract available
December 2024
WARKENTIN MT, Tammemagi MC, Vakil E, Bedard ELR, et al Brief Report: Evaluating Early-Stage Lung Cancer Survival Patterns in Patients at
the Upper Age Limit for Lung Cancer Screening.
J Thorac Oncol. 2024 Dec 30:S1556-0864(24)02546. PubMedAbstract available
LEE JB, Choi SJ, Shim HS, Park BJ, et al Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell
lung cancer (NORA).
J Thorac Oncol. 2024 Dec 26:S1556-0864(24)02544. PubMedAbstract available
GABE R, Crosbie PAJ, Vulkan D, Bailey H, et al Prospective evaluation of lung cancer screening eligibility criteria and lung
cancer detection in the Yorkshire Lung Screening Trial.
J Thorac Oncol. 2024 Dec 19:S1556-0864(24)02535. PubMedAbstract available
PASSIGLIA F, Listi A, Bironzo P, Merlini A, et al Actionable non-small cell lung cancer mutation identification by comprehensive
genomic profiling for clinical trial enrollment: the European Program for the
ROutine testing of Patients with Advanced lung cancer (EPROPA).
J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02529. PubMedAbstract available
SWALDUZ A, Schiffler C, Curcio H, Ambasager B, et al LIBELULE: a randomized phase III study to evaluate the clinical relevance of
early liquid biopsy in patients with suspicious metastatic lung cancer.
J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02530. PubMedAbstract available
TAVERNARI D, Borgeaud M, Liu X, Kaushal P, et al Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and
Uncommon Mutations in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02531. PubMedAbstract available
HOFFMANN H, Nicholson AG, Detterbeck FC, Tsao MS, et al The International Association for the Study of Lung Cancer Lung Cancer Staging
Project: Application and Interpretation of the Residual Tumor (R) Classification
for Lung Cancer. Results from an International Survey among Pathologists and
Thoracic Surge
J Thorac Oncol. 2024 Dec 13:S1556-0864(24)02526. PubMedAbstract available
KIM SY, Silvestri GA, Kim YW, Kim RY, et al Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A
Nationwide Population-Based Study.
J Thorac Oncol. 2024 Dec 9:S1556-0864(24)02503. PubMedAbstract available
PHILLIPS WJ, Watson AS, Camidge DR The use of investigator-assigned subjective or judgmental efficacy and toxicity
reporting in early phase clinical trials of lung cancer treatments.
J Thorac Oncol. 2024 Dec 4:S1556-0864(24)02498. PubMedAbstract available
XU X, Xie J, Luo Z Strengthening the Evidence: Expanding Research on Passive Smoking and Lung
Cancer.
J Thorac Oncol. 2024;19:e94-e95. PubMed
LI Z, Liu J, Liu H, Wu C, et al Comment on "A Real-World Assessment of Stage I Lung Cancer Through Electronic
Nose Technology".
J Thorac Oncol. 2024;19:e89-e90. PubMed
ZHOU RX, Ye DW Reply to the Letter to the Editor: The Relationship Between Air Pollution and
Lung Cancer: Differences in Sensitivity Across Regions and Populations.
J Thorac Oncol. 2024;19:e82-e84. PubMed
WANG L, Wang Z, Wang G The Relationship Between Air Pollution and Lung Cancer: Differences in
Sensitivity Across Regions and Populations.
J Thorac Oncol. 2024;19:e81-e82. PubMed
JENSEN SO, Moore DA, Surani AA, Crosbie PAJ, et al Second Primary Lung Cancer-Potential Areas of Ambiguity.
J Thorac Oncol. 2024;19:e101-e102. PubMed
NIU Y, Xie J, Li Z Second Primary Lung Cancer-Potential Areas of Ambiguity.
J Thorac Oncol. 2024;19:e100-e101. PubMed
GUISSEVE A, Mualinque A, Cossa M, Jerez AD, et al Lung Cancer in Mozambique.
J Thorac Oncol. 2024;19:1599-1605. PubMed
TONG BC, Stinchcombe TE Lung Cancer Screening and Early Detection Terminology: Time to Sing From the Same
Song Sheet.
J Thorac Oncol. 2024;19:1589-1590. PubMed
KOZONO D, Hua X, Wu MC, Tolba KA, et al Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung
Cancers (SWOG S1400).
J Thorac Oncol. 2024;19:1618-1629. PubMedAbstract available
November 2024
HEERSCHE N, Lanser DAC, Muntinghe-Wagenaar MB, Mohmaed Ali MI, et al Sex and common germline variants impact the toxicity profile and pharmacokinetics
of alectinib: a nation-wide cohort study in patients with ALK-positive non-small
cell lung cancer.
J Thorac Oncol. 2024 Nov 29:S1556-0864(24)02488. PubMedAbstract available
KAZI A, Kantilal Vasiyani HK, Ghosh D, Bandyopadhyay D, et al FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C
Lung Cancer.
J Thorac Oncol. 2024 Nov 25:S1556-0864(24)02485. PubMedAbstract available
IGNATIUS OU SH, Solomon BJ, Besse B, Bearz A, et al Brief Report: Final overall survival and long-term safety of lorlatinib in
patients with ALK-positive non-small cell lung cancer from the pivotal phase 2
study.
J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02484. PubMedAbstract available
DAMARAJU V, Krushna Karri JK, Gandrakota G, Marimuthu Y, et al Low dose computed tomography for lung cancer screening in Tuberculosis endemic
countries: A Systematic Review and Meta-analysis.
J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02483. PubMedAbstract available
LEVY A, Rusthoven CG, Brown PD, Le Pechoux C, et al PCI for Patients with Small Cell Lung Cancer: A New Perspective in the
Immunotherapy Era.
J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02446. PubMedAbstract available
ZHAO S, Zhou H, Yang N, Wang Z, et al Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in
ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b
trial.
J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02445. PubMedAbstract available
TUMINELLO S, Flores R, Untalan M, Ivic-Pavlicic T, et al Predicted effect of incidental pulmonary nodule findings on Non-Small Cell Lung
Cancer mortality.
J Thorac Oncol. 2024 Nov 12:S1556-0864(24)02444. PubMedAbstract available
ECHEPARE M, Picabea B, Arricibita A, Teijeira A, et al DSTYK Inhibition Sensitizes Non-Small Cell Lung Cancer To Taxane-Based
Chemotherapy.
J Thorac Oncol. 2024 Nov 11:S1556-0864(24)02438. PubMedAbstract available
GRAY JE, Schenker M, Nahit Sendur MA, Leonova V, et al The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab
plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell
Lung Cancer.
J Thorac Oncol. 2024 Nov 7:S1556-0864(24)02435. PubMedAbstract available
KARIM NA, Miao J, Reckamp KL, Gay CM, et al Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab +
talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung
cancer. S1929.
J Thorac Oncol. 2024 Nov 4:S1556-0864(24)02431. PubMedAbstract available
OLTEANU GE, Vigdorovits A, Barna RA, Mazilu L, et al Lung Cancer in Romania.
J Thorac Oncol. 2024;19:1492-1503. PubMed
D'AMOURS MF, Hughesman CB, Yip ST, Ho C, et al The Game is Afoot - Seeking Early-Stage Lung Cancer Circulating Tumor DNA.
J Thorac Oncol. 2024;19:1479-1481. PubMed
ADJEI AA How Can We Conquer Lung Cancer?
J Thorac Oncol. 2024;19:1477-1478. PubMed
KINDLER HL, Rosenthal A, Giroux DJ, Nowak AK, et al The International Association for the Study of Lung Cancer Mesothelioma Staging
Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the
TNM Classification for Pleural Mesothelioma.
J Thorac Oncol. 2024;19:1564-1577. PubMedAbstract available
PARIKH K, Dimou A, Leventakos K, Mansfield AS, et al Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of
First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK
Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database.
J Thorac Oncol. 2024;19:1539-1549. PubMedAbstract available
HONG TH, Hwang S, Dasgupta A, Abbosh C, et al Clinical Utility of Tumor-Naive Presurgical Circulating Tumor DNA Detection in
Early-Stage NSCLC.
J Thorac Oncol. 2024;19:1512-1524. PubMedAbstract available
October 2024
HOCHMAIR M, Schenker M, Dols MC, Kim TM, et al Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous
Non-Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus
Chemotherapy.
J Thorac Oncol. 2024 Oct 28:S1556-0864(24)02420. PubMedAbstract available
CHEN Z, Wu L, Wang Q, Yu Y, et al Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line
treatment for extensive-stage small-cell lung cancer: results of a phase Ib
clinical trial.
J Thorac Oncol. 2024 Oct 26:S1556-0864(24)02421. PubMedAbstract available
UMEMURA S, Udagawa H, Ikeda T, Murakami H, et al Clinical significance of a prospective large genomic screening for small-cell
lung cancer: the genetic classification and a biomarker driven phase II trial of
gedatolisib.
J Thorac Oncol. 2024 Oct 10:S1556-0864(24)02378. PubMedAbstract available
PETERS S, Paz-Ares LG, Reck M, Carbone DP, et al Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based
Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1
<1%: a Pooled Analysis.
J Thorac Oncol. 2024 Oct 4:S1556-0864(24)02355. PubMedAbstract available
LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al A Response to the Letter to the Editor: "Comment on Stereotactic Body
Radiotherapy for Centrally Located Inoperable Early Stage NSCLC: EORTC
22113-08113 LungTech Phase II Trial Results".
J Thorac Oncol. 2024;19:e57-e59. PubMed
XU Z, Jiang J, Guo H, Zhao D, et al Comment on "Stereotactic Body Radiotherapy for Centrally Located Inoperable
Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
J Thorac Oncol. 2024;19:e56-e57. PubMed
RAMI-PORTA R, Call S, Sanz-Santos J Reply to "Impact of the Ninth IASLC TNM Classification on Endobronchial
Ultrasound for Lung Cancer Staging" by Faria et al.
J Thorac Oncol. 2024;19:e55-e56. PubMed
FARIA N, Costa MI, Lacerda C, Sucena M, et al Impact of the Ninth International Association for the Study of Lung Cancer TNM
Classification on Endobronchial Ultrasound for Lung Cancer Staging.
J Thorac Oncol. 2024;19:e53-e55. PubMed
KOHNO T, Mochizuki A Response to Letter to the Editor.
J Thorac Oncol. 2024;19:e52-e53. PubMed
GU X, Han Z, Shi W Comment on "Passive Smoking-Induced Mutagenesis as a Promoter of Lung
Carcinogenesis".
J Thorac Oncol. 2024;19:e51-e52. PubMed
ZHUANG WT, Hu LY, Fang WF Response to Commentary on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage
Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
J Thorac Oncol. 2024;19:e50-e51. PubMed
PAN Y Comment on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and
Mediate Innate Immune Evasion Through Up-Regulation of CD47".
J Thorac Oncol. 2024;19:e49-e50. PubMed
SHI Y A Response to the Letter to the Editor: Response to Ficonalkib's Promise and the
Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment.
J Thorac Oncol. 2024;19:e48. PubMed
GE MW, Chen HL Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive
NSCLC Treatment.
J Thorac Oncol. 2024;19:e47-e48. PubMed
CABALLE-PEREZ E, Cabrera-Miranda L, Arrieta O Exploring EGFR Mutations in Resected Stage I-III NSCLC in Low- and Middle-Income
Countries: Bridging the Gap in Global Cancer Care.
J Thorac Oncol. 2024;19:1367-1369. PubMed
PUJOL JL, Erich Eberhardt WE Familial Lung Cancers Caused by EGFR Germline Mutations: The Frequency Is
Probably Underestimated but Specific Genotypic Features and Some Particular
Disease Characteristics Should Help Their Screening.
J Thorac Oncol. 2024;19:1364-1366. PubMed
SOO RA, Reungwetwattana T, Perroud HA, Batra U, et al Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC:
Results From the EARLY-EGFR Study.
J Thorac Oncol. 2024;19:1449-1459. PubMedAbstract available
PAN K, Owens J, Elamin Y, Lu C, et al Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With
EGFR Germline Mutations.
J Thorac Oncol. 2024;19:1438-1448. PubMedAbstract available
BUROTTO M, Zvirbule Z, Alvarez R, Chewaskulyong B, et al Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of
Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or
Metastatic NSCLC.
J Thorac Oncol. 2024;19:1460-1466. PubMedAbstract available
September 2024
SAID BI, Geng Y, Badiyan SN, Bang A, et al Accelerated hypofractionated radiotherapy for locally-advanced non-small cell
lung cancer: A systematic review from the International Association for the Study
of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.
J Thorac Oncol. 2024 Sep 28:S1556-0864(24)02353. PubMedAbstract available
PARK HS, Rimner A, Amini A, Chang JY, et al Executive Summary of the American Radium Society(R) (ARS) Appropriate Use Criteria
(AUC) for Non-Small Cell Lung Cancer in a Central/Ultra-Central Location:
Systematic Review and Guidelines.
J Thorac Oncol. 2024 Sep 11:S1556-0864(24)02268. PubMedAbstract available
NASSAR AH, Jayakrishnan R, Feng J, Shepherd F, et al Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation
After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer.
J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02265. PubMedAbstract available
CHEN H, Yang S, Wang L, Wu Y, et al High-dose Furmonertinib in patients with EGFR-mutated non-small cell lung cancer
and leptomeningeal metastases: A prospective real-world study.
J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02269. PubMedAbstract available
HORNE A, Harada K, Brown KD, Lee Min Chua K, et al Erratum to "Treatment response biomarkers: working towards personalised
radiotherapy for lung cancer. [Journal of Thoracic Oncology Vol. 19 No. 8:
1164-1185]".
J Thorac Oncol. 2024 Sep 5:S1556-0864(24)00775. PubMed
ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al A Response to the Letter to the Editor: Comment on "Clinical Utility of
Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated
With Sotorasib".
J Thorac Oncol. 2024;19:e44-e45. PubMed
JIANG Y, Zhang L Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced
KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
J Thorac Oncol. 2024;19:e43. PubMed
LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al A Response to the Letter to the Editor: The Role of Personalization and
Standardization in Stereotactic Body Radiation Therapy.
J Thorac Oncol. 2024;19:e41-e43. PubMed
ROMA L, Bubendorf L Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic
Carcinoma.
J Thorac Oncol. 2024;19:e38-e39. PubMed
ZHOU L, Li M, Li W Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic
Carcinoma.
J Thorac Oncol. 2024;19:e37-e38. PubMed
TUMINELLO S, Gulati S, Ivic-Pavlicic T, Flores R, et al Response to: "The Value of Incidental Imaging for Early Stage Lung Cancer in
High-Risk Nonscreening Cohort: Some Additional Considerations?".
J Thorac Oncol. 2024;19:e36. PubMed
NIU Y, Xie J, Li Z The Value of Incidental Imaging for Early-Stage Lung Cancer in a High-Risk
Non-Screening Cohort: Some Additional Considerations?
J Thorac Oncol. 2024;19:e34-e35. PubMed
HIGASHIYAMA RI, Yoshida T A Response to the Letter to the Editor: Safety Implications of Switching
Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in
Patients With Advanced NSCLC.
J Thorac Oncol. 2024;19:e33-e34. PubMed
HAN Z, Liu L, Jiang Y Suggestions for the predictive factors related to irAES and research
methods during dose switching of pembrolizumab treatment in patients with
advanced NSCLC.
J Thorac Oncol. 2024;19:e31-e32. PubMed
ANDERSEN H, Aro M, Kaarteenaho R, Koivunen J, et al Lung Cancer in Finland.
J Thorac Oncol. 2024;19:1265-1271. PubMed
YANG CY, Lee MR, Yang PC Beyond Low-Dose Computed Tomography: Emerging Diagnostic Tools for Early Lung
Cancer Detection.
J Thorac Oncol. 2024;19:1261-1264. PubMed
ROSSI S, Costa R, di Federico A, Lo Bianco F, et al Histopathological Evidence for a Non-Inflammatory Mechanism in
Osimertinib-Induced Myopathy: A Case Report.
J Thorac Oncol. 2024;19:1352-1355. PubMedAbstract available
LEVY A, Adebahr S, Hurkmans C, Ahmed M, et al Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage
NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results.
J Thorac Oncol. 2024;19:1297-1309. PubMedAbstract available
ROMA L, Ercan C, Conticelli F, Akyurek N, et al Tracing Tumor Heterogeneity of Pleomorphic Carcinoma of the Lung.
J Thorac Oncol. 2024;19:1284-1296. PubMedAbstract available
GILL RR, Nowak AK, Giroux DJ, Eisele M, et al The International Association for the Study of Lung Cancer Mesothelioma Staging
Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth
Edition of the TNM Classification for Pleural Mesothelioma.
J Thorac Oncol. 2024;19:1310-1325. PubMedAbstract available
August 2024
ZHOU Q, Meng X, Sun L, Huang D, et al Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with
advanced non-small cell lung cancer: results from a phase 2 pivotal study.
J Thorac Oncol. 2024 Aug 8:S1556-0864(24)00762. PubMedAbstract available
HUBER RM, Cavic M, Balata H, Kitts AB, et al From the IASLC Early Detection and Screening Committee Terminology Issues in
Screening and Early Detection of Lung Cancer - IASLC Early Detection and
Screening Committee Expert Group Recommendations.
J Thorac Oncol. 2024 Aug 2:S1556-0864(24)00747. PubMedAbstract available
ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With
Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
J Thorac Oncol. 2024;19:e29-e30. PubMed
KOSAKA N, Kataoka Y Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With
Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
J Thorac Oncol. 2024;19:e28. PubMed
CAMERON RB, Hines JB, Torri V, Garassino MC, et al A Response Letter by Cameron et al.
J Thorac Oncol. 2024;19:e26-e28. PubMed
PONVILAWAN B, Subramanian J, Bansal D The Number of Chemoimmunotherapy Cycles and Clinical Outcomes in Resectable
NSCLC.
J Thorac Oncol. 2024;19:e24-e26. PubMed
TRISOLINI R The Devil Is in the Details: A Hidden Obstacle to Implementing the Proposed
Revision of the N Descriptors in the Ninth Edition of the TNM Classification for
Lung Cancer.
J Thorac Oncol. 2024;19:e23. PubMed
KUBO N Response to Letter to the Editor.
J Thorac Oncol. 2024;19:e22. PubMed
SHI L, Bao Z Accurate Prognostic Factor for Carbon-Ion Radiotherapy in Operable Stage I NSCLC.
J Thorac Oncol. 2024;19:e21-e22. PubMed
SILVESTRI GA, Young RP, Tanner NT, Mazzone P, et al Screening Low-Risk Individuals for Lung Cancer: The Need May Be Present, but the
Evidence of Benefit Is Not.
J Thorac Oncol. 2024;19:1155-1163. PubMedAbstract available
MAKAREM M, Janne PA "Tumor-Free Survival" Outweighs the Side Effects of Combined Anti-EGF Therapy and
Chemotherapy in Patients With NSCLC.
J Thorac Oncol. 2024;19:1151-1154. PubMed
ZHENG MM, Wu YL "Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy
and Chemotherapy in Patients With NSCLC.
J Thorac Oncol. 2024;19:1146-1150. PubMed
LAISAAR T, Innos K, Jaal J, Oselin K, et al Lung Cancer in Estonia.
J Thorac Oncol. 2024;19:1138-1145. PubMed
WOODARD GA, Jablons DM Shades of Gray: Do Never Smokers Benefit From Lung Cancer Screening Programs?
J Thorac Oncol. 2024;19:1135-1137. PubMed
TURK MA Editorial Comment: Validation Study for the N Descriptor of the Newly Proposed
9th Edition of the TNM Staging System Proposed by the International Association
for the Study of Lung Cancer.
J Thorac Oncol. 2024;19:1133-1134. PubMed
PERRONE F, Leonetti A, Tiseo M, Facchinetti F, et al Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in "PD-L1
Negative" NSCLC.
J Thorac Oncol. 2024;19:1128-1132. PubMed
GRAY SG, Mutti L, Meirson T Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer.
J Thorac Oncol. 2024;19:1125-1127. PubMed
HU LY, Zhuang WT, Chen MJ, Liao J, et al EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate
Innate Immune Evasion Through Up-Regulation of CD47.
J Thorac Oncol. 2024;19:1186-1200. PubMedAbstract available
WOLF AS, Eisele M, Giroux DJ, Gill R, et al The International Association for the Study of Lung Cancer Pleural Mesothelioma
Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of
the TNM Classification of Pleural Mesothelioma.
J Thorac Oncol. 2024;19:1242-1252. PubMedAbstract available
July 2024
VAN ROSSUM PSN, Wolfhagen N, van Bockel LW, Coremans IEM, et al Real-world acute toxicity and 90-day mortality in patients with stage I non-small
cell lung cancer treated with stereotactic body radiotherapy.
J Thorac Oncol. 2024 Jul 25:S1556-0864(24)00684. PubMedAbstract available
JENSEN SO, Moore DA, Surani AA, Crosbie PA, et al Second Primary Lung Cancer - an emerging issue in lung cancer survivors.
J Thorac Oncol. 2024 Jul 24:S1556-0864(24)00683. PubMedAbstract available
GRAY JE, Markovets A, Reungwetwattana T, Majem M, et al Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR
Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During
Treatment: Data From FLAURA and AURA3.
J Thorac Oncol. 2024 Jul 17:S1556-0864(24)00676. PubMedAbstract available
JUN S, Shukla NA, Durm G, Hui AB, et al Analysis of Circulating Tumor DNA Predicts Outcomes of Short Course Consolidation
Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.
J Thorac Oncol. 2024 Jul 4:S1556-0864(24)00664. PubMedAbstract available
LIN YL, Wang GS, Wei JC Rheumatoid Arthritis and Risk of Lung Cancer.
J Thorac Oncol. 2024;19:e15-e16. PubMed
YANG JJ, Wen W, Zheng W, Shu XO, et al "Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in
Asia".
J Thorac Oncol. 2024;19:e14-e15. PubMed
SHEN LT, Chen HL Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in
Asia.
J Thorac Oncol. 2024;19:e13-e14. PubMed
AFRIYIE-MENSAH JS, Dadzie MA, Vanderpuye VDNK, Calys-Tagoe B, et al Lung Cancer in Ghana.
J Thorac Oncol. 2024;19:966-972. PubMed
MOCHIZUKI A, Shiraishi K, Honda T, Higashiyama RI, et al Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis.
J Thorac Oncol. 2024;19:984-994. PubMedAbstract available
June 2024
SPICER JD, Cascone T, Wynes MW, Ahn MJ, et al Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung
Cancer (NSCLC): Consensus Recommendations from the International Association for
the Study of Lung Cancer (IASLC).
J Thorac Oncol. 2024 Jun 18:S1556-0864(24)00627. PubMedAbstract available
HSU CK, Lai CC Association Between Rheumatoid Arthritis and the Risk of Lung Cancer.
J Thorac Oncol. 2024;19:e9. PubMed
URBANSKA EM, Sorensen JB, Santoni-Rugiu E Finding One Treatment for All Advanced EGFR-positive NSCLC-An Infinite Task.
J Thorac Oncol. 2024;19:e11-e12. PubMed
CHO MH, Cho JH, Shin DW In Response.
J Thorac Oncol. 2024;19:e10. PubMed
RICCIUTI B, Garassino MC Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC.
J Thorac Oncol. 2024;19:877-882. PubMed
DICKHOFF C, Heineman DJ, van Dorp M, Senan S, et al The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal
and Neoadjuvant Therapy Should Be the Standard.
J Thorac Oncol. 2024;19:862-865. PubMed
UGALDE FIGUEROA P, Lacroix V, Van Schil PE Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and
Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint.
J Thorac Oncol. 2024;19:858-861. PubMed
LI MS, Ou SI Iruplinalkib (WX-0593), the Seventh ALK Tyrosine Kinase Inhibitor Approved in
People's Republic of China With More to Come.
J Thorac Oncol. 2024;19:855-857. PubMed
PECCATORI FA, Florez N, Imbimbo M From Approximation to Precision: Fertility and Pregnancy Questions in Young
Patients With Lung Cancer.
J Thorac Oncol. 2024;19:852-854. PubMed
May 2024
ROCCO G, Pennazza G, Tan KS, Vanstraelen S, et al A real-world assessment of stage I lung cancer through electronic nose
technology.
J Thorac Oncol. 2024 May 16:S1556-0864(24)00211. PubMedAbstract available
BILLE A, Ripley RT, Giroux DJ, Gill RR, et al The International Association for the Study of Lung Cancer Mesothelioma Staging
Project: Proposals for the "N" Descriptors in the Forthcoming Ninth Edition of
the TNM Classification for Pleural Mesothelioma.
J Thorac Oncol. 2024 May 9:S1556-0864(24)00208. PubMedAbstract available
NOWAK AK, Giroux DJ, Eisele M, Rosenthal A, et al The International Association for the Study of Lung Cancer Pleural Mesothelioma
Staging Project: Proposal for Revision of the TNM Stage Groupings in the
Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma.
J Thorac Oncol. 2024 May 9:S1556-0864(24)00207. PubMedAbstract available
NASSAR AH, Kim SY, Adib E, Naqash AR, et al Response letter by Nassar et al.
J Thorac Oncol. 2024;19:e7-e8. PubMed
CHEN CY, Wang GS, Wei JC Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent
Chemoradiation in Unresectable EGFR-Mutant NSCLC".
J Thorac Oncol. 2024;19:e6-e7. PubMed
ZHAO B, Yao L, Ma W Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in
Unresectable EGFR-Mutant NSCLC.
J Thorac Oncol. 2024;19:e5-e6. PubMed
SRINIVASALU VK, Patnaik RS, Kiong LS, Justin JS, et al Lung Cancer in Brunei Darussalam.
J Thorac Oncol. 2024;19:698-705. PubMed
LI Y, Adusumilli PS, Chou TY, Kadota K, et al Pro: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible
Artifact?".
J Thorac Oncol. 2024;19:677-697. PubMedAbstract available
BLAAUWGEERS H, Dickhoff C, Pelosi G, Timens W, et al Con: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible
Artifact?".
J Thorac Oncol. 2024;19:671-676. PubMed
SHIH JY ERBB2 Amplification in NSCLC: How Many Faces?
J Thorac Oncol. 2024;19:668-670. PubMed
ISHIKAWA S Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes,
Validating Neoadjuvant Therapies, and Improving Precision.
J Thorac Oncol. 2024;19:666-667. PubMed
WOODARD GA, Dacic S Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
J Thorac Oncol. 2024;19:663-665. PubMed
LUO J, Sanchez M, Lee E, Hertzler H, et al Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
J Thorac Oncol. 2024;19:829-838. PubMedAbstract available
OU SI, Hagopian GG, Zhang SS, Nagasaka M, et al Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural
Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central
beta-Sheet 6 [Cbeta6] Mutation [L2086F]).
J Thorac Oncol. 2024;19:706-718. PubMedAbstract available
April 2024
GADGEEL SM, Rodriguez-Abreu D, Halmos B, Garassino MC, et al Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With
Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled
Analysis of Outcomes After 5 Years of Follow-Up.
J Thorac Oncol. 2024 Apr 18:S1556-0864(24)00169. PubMedAbstract available
ERNST SM, van Marion R, Atmodimedjo PN, de Jonge E, et al Clinical utility of circulating tumor DNA in patients with advanced
KRAS(G12C)-mutated non-small cell lung cancer treated with sotorasib.
J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00165. PubMedAbstract available
HORNE A, Harada K, Brown KD, Chua KLM, et al Treatment response biomarkers: working towards personalised radiotherapy for lung
cancer.
J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00164. PubMedAbstract available
KIM IH, Lee GD, Choi S, Kim HR, et al Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the
TNM Staging System Proposed by the International Association for the Study of
Lung Cancer.
J Thorac Oncol. 2024 Apr 11:S1556-0864(24)00160. PubMedAbstract available
SHUKLA V, Wang H, Varticovski L, Baek S, et al Genome-wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor
and Potential Therapeutic Target in Small Cell Lung Cancer.
J Thorac Oncol. 2024 Apr 5:S1556-0864(24)00131. PubMedAbstract available
DETTERBECK FC, Ostrowski M, Hoffmann H, Rami-Porta R, et al The IASLC Lung Cancer Staging Project: Proposals for Revision of the
Classification of Residual Tumor after Resection for the Forthcoming (9(th))
Edition of the TNM Classification of Lung Cancer.
J Thorac Oncol. 2024 Apr 1:S1556-0864(24)00129. PubMedAbstract available
CHANG CL, Lin KC, Chen WM, Shia BC, et al Correspondence: Intensity-Modulated Proton Therapy Versus Intensity-Modulated
Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic
Issues.
J Thorac Oncol. 2024;19:e2-e4. PubMed
CHIOU CC, Lai TY Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for
Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
J Thorac Oncol. 2024;19:e1-e2. PubMed
SMESSEIM I, Baas P Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural
Mesothelioma, Despite the Real-World Results From Australia.
J Thorac Oncol. 2024;19:547-550. PubMed
GRAY SG, Meirson T, Mutti L Based on the Real-World Results From Australia, Immunotherapy Is Not a Good
Option for Patients With Mesothelioma.
J Thorac Oncol. 2024;19:541-546. PubMed
SAIFO M, Alali M, Alhabeb H, Awak M, et al Lung Cancer in Syria.
J Thorac Oncol. 2024;19:534-540. PubMed
SHOENBILL KA, Goldstein AO Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening.
J Thorac Oncol. 2024;19:531-533. PubMed
ZHU Z, Chen H Additional Evidence for Postoperative Radiation Therapy on Thymic Carcinoma.
J Thorac Oncol. 2024;19:528-530. PubMed
LEE JB, Nagasaka M Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind
Men and the Elephant Stage?
J Thorac Oncol. 2024;19:525-527. PubMed
LEONG TL, McWilliams A, Wright GM Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening.
J Thorac Oncol. 2024;19:522-524. PubMed
DWYER LJ, Singhal N, Yu B, Kao S, et al Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib:
A Case Report.
J Thorac Oncol. 2024;19:650-652. PubMedAbstract available
RIMNER A, Ahmad U, Lobaugh SM, Zhang Z, et al Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the
International Thymic Malignancy Interest Group/European Society of Thoracic
Surgeons Database.
J Thorac Oncol. 2024;19:626-635. PubMedAbstract available
MCNAMEE N, Harvey C, Gray L, Khoo T, et al Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in
Pleural Mesothelioma-RIOMeso.
J Thorac Oncol. 2024;19:636-642. PubMedAbstract available
NEL AE, Pavlisko EN, Roggli VL The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune
Senescence in Mesothelioma Development and Response to Immunotherapy.
J Thorac Oncol. 2024;19:551-564. PubMedAbstract available
March 2024
TRAVIS WD, Eisele M, Nishimura KK, Aly R, et al The IASLC Lung Cancer Staging Project: Recommendation to Introduce Spread Through
Air Spaces (STAS) as a Histologic Descriptor in the 9(th) Edition of the TNM
Classification of Lung Cancer.Analysis of 4,061 Pathologic Stage I Non-Small cell
Lung Carci
J Thorac Oncol. 2024 Mar 18:S1556-0864(24)00122. PubMedAbstract available
BORGEAUD M, Parikh K, Banna GL, Kim F, et al Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer
- A Systematic Review.
J Thorac Oncol. 2024 Mar 16:S1556-0864(24)00123. PubMedAbstract available
HINES JB, Cameron RB, Esposito A, Kim L, et al Evaluation of MPR and pCR as surrogate endpoints for survival in randomized
controlled trials of neoadjuvant immune checkpoint blockade in resectable in
non-small cell lung cancer.
J Thorac Oncol. 2024 Mar 8:S1556-0864(24)00117. PubMedAbstract available
CHENG Y, Fan Y, Zhao Y, Huang D, et al Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and
Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
(RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized,
Phase 3 Clinical Trial
J Thorac Oncol. 2024 Mar 7:S1556-0864(24)00115. PubMedAbstract available
RAMI-PORTA R, Nishimura KK, Giroux DJ, Detterbeck F, et al The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage
Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung
Cancer.
J Thorac Oncol. 2024 Mar 4:S1556-0864(24)00079. PubMedAbstract available
KIM BG, Yoon S, Lee SY, Sohn JW, et al How Does Rheumatoid Arthritis Increase the Risk of Lung Cancer?
J Thorac Oncol. 2024;19:509-510. PubMed
WERNER RS, Curioni-Fontecedro A, Mauti LA, Addeo A, et al Lung Cancer in Switzerland.
J Thorac Oncol. 2024;19:385-394. PubMed
TEN HAAF K Considerations for Enhancing Lung Cancer Risk Prediction and Screening in Asian
Populations.
J Thorac Oncol. 2024;19:373-375. PubMed
LI CP, Tsai RY, Chang HC, Gau SY, et al Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC.
J Thorac Oncol. 2024;19:507-508. PubMed
CHEN LN, Lee ATM, Nagasaka M, Ou SI, et al Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for
All Advanced EGFR+ NSCLC.
J Thorac Oncol. 2024;19:380-384. PubMed
LIM SM, Lee JB, Cho BC Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment
for All Advanced EGFR+ NSCLC.
J Thorac Oncol. 2024;19:376-379. PubMed
YALAMANCHALI A, Hassan KA MUC1-C: The Occam Razor of Osimertinib Resistance?
J Thorac Oncol. 2024;19:370-372. PubMed
DAMMEIJER F, Dumoulin DW, Aerts JGJV Anti-Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1
Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.
J Thorac Oncol. 2024;19:366-369. PubMed
CANI M, Novello S, Bironzo P Mismatch Repair Deficiency in Lung Tumors: Adding a New Layer of Complexity on
Pie Slices.
J Thorac Oncol. 2024;19:363-365. PubMed
BORCZUK AC Invasive Size in Lung Adenocarcinoma-Reproducible Criteria, More Accurate
Staging.
J Thorac Oncol. 2024;19:360-362. PubMed
YANG SR, Gedvilaite E, Ptashkin R, Chang J, et al Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct
Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational
Burden, and Recurrent Somatic MLH1 Inactivation.
J Thorac Oncol. 2024;19:409-424. PubMedAbstract available
February 2024
FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M
Descriptors in the Forthcoming 9th edition of the TNM Classification of Lung
Cancer.
J Thorac Oncol. 2024 Feb 4:S1556-0864(24)00060. PubMedAbstract available
ZHOU RX, Liao HJ, Hu JJ, Xiong H, et al Global burden of lung cancer attributable to household fine particulate matter
pollution in 204 countries and territories, 1990-2019.
J Thorac Oncol. 2024 Feb 2:S1556-0864(24)00034. PubMedAbstract available
TORASAWA M, Horinouchi H A Response to the Letter to the Editor: "A Paradigm Shift in First-Line Treatment
Can Have Many Implications for Second-Line Treatment".
J Thorac Oncol. 2024;19:351-352. PubMed
NISHIMURA T A Paradigm Shift in First-Line Treatment Can Have Many Implications For
Second-Line Treatment.
J Thorac Oncol. 2024;19:350. PubMed
HORITA N, Takase-Minegishi K Information Bias Might Exaggerate Lung Cancer Risk of Patients With Rheumatoid
Arthritis.
J Thorac Oncol. 2024;19:348. PubMed
CHANG HC, Gau SY Real-World Evidence of the Association Between Rheumatoid Arthritis and Lung
Cancer.
J Thorac Oncol. 2024;19:346. PubMed
YUAN C, Huang R, Wang Y An Error in Modeling and the Selection of Independent Radiomics Variables Need
Caution.
J Thorac Oncol. 2024;19:344-345. PubMed
BERMAS BL, Gerber DE The Joint Problem of Rheumatoid Arthritis and Lung Cancer.
J Thorac Oncol. 2024;19:196-198. PubMed
VOKES EE, Mornex F, Sezer A, Cheng Y, et al Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT
Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2
Randomized Study.
J Thorac Oncol. 2024;19:285-296. PubMedAbstract available
REMON J, Saw SPL, Cortiula F, Singh PK, et al Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current
Evidence and Future Challenges.
J Thorac Oncol. 2024;19:199-215. PubMedAbstract available
DACIC S, Cao X, Bota-Rabassedas N, Sanchez-Espiridion B, et al Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the
Comprehensive Morphologic Assessment.
J Thorac Oncol. 2024;19:273-284. PubMedAbstract available
OWONIKOKO TK SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere
Relic or a Valuable Treasure to Keep?
J Thorac Oncol. 2024;19:193-195. PubMed
LE X Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC.
J Thorac Oncol. 2024;19:190-192. PubMed
LEE JH Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?
J Thorac Oncol. 2024;19:187-189. PubMed
SHIRAISHI Y, Tokito T, Toyozawa R, Inagaki C, et al Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic
Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
J Thorac Oncol. 2024;19:337-343. PubMedAbstract available
January 2024
SHI Y, Hu X, Li X, Gong C, et al Ficonalkib (SY-3505) in Advanced ALK-Positive Non-Small-Cell Lung Cancer: A
Multicenter, Open-Label, Single-Arm, Phase I/? Study.
J Thorac Oncol. 2024 Jan 29:S1556-0864(24)00035. PubMedAbstract available
SHI Y, Chen J, Yang R, Wu H, et al Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or
metastatic ALK-positive non-small cell lung cancer: interim analysis of a
randomized, open-label, phase III study (INSPIRE).
J Thorac Oncol. 2024 Jan 25:S1556-0864(24)00033. PubMedAbstract available
NASSAR AH, Kim SY, Aredo JV, Feng J, et al Consolidation Osimertinib versus Durvalumab versus Observation following
Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer:
A Multicenter Retrospective Cohort Study.
J Thorac Oncol. 2024 Jan 24:S1556-0864(24)00032. PubMedAbstract available
SIMONS E, Camidge DR Lung cancer oncogene-directed therapy, fertility and pregnancy.
J Thorac Oncol. 2024 Jan 5:S1556-0864(24)00023. PubMedAbstract available
YU S, Feng J Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III,
Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".
J Thorac Oncol. 2024;19:173-174. PubMed
TANIZAKI J, Hayashi H Unraveling Pseudo Kidney Injury: The Significance of Understanding Our "MATE" in
Molecular-Targeted Therapies.
J Thorac Oncol. 2024;19:15-17. PubMed
BATAH H, Majeed Z, Moudgil R Tale of Two Cs: Inter-Relationship Between Cardiovascular and Lung Cancer.
J Thorac Oncol. 2024;19:13-14. PubMed
FANG W, Girard N, Cilento V, Goren E, et al The International Association for the Study of Lung Cancer Thymic Epithelial
Tumors Staging Project: Proposals for the N and the M Components for
the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2024;19:52-70. PubMedAbstract available
CHEN MF, Harada G, Liu D, DeMatteo R, et al Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can
Lead to "False" Decreases in Renal Function.
J Thorac Oncol. 2024;19:153-159. PubMedAbstract available
UDAGAWA H, Nilsson MB, Robichaux JP, He J, et al HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications
for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
J Thorac Oncol. 2024;19:106-118. PubMedAbstract available
HAMADA A, Suda K, Nishino M, Obata K, et al Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in
EGFR Exon 20 Insertion.
J Thorac Oncol. 2024;19:71-79. PubMedAbstract available
LAM S, Wynes MW, Connolly C, Ashizawa K, et al The International Association for the Study of Lung Cancer Early Lung Imaging
Confederation Open-Source Deep Learning and Quantitative Measurement Initiative.
J Thorac Oncol. 2024;19:94-105. PubMedAbstract available
TAGLIAMENTO M, Di Maio M, Remon J, Bironzo P, et al Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1
and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for
Unresectable Pleural Mesothelioma.
J Thorac Oncol. 2024;19:166-172. PubMedAbstract available
December 2023
YANG JC, Han B, De La Mora Jimenez E, Lee JS, et al Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non?Small-Cell
Lung Cancer With PD-L1 Tumor Proportion Score >/=1% (LEAP-007): A Randomized,
Double-Blind, Phase 3 Trial.
J Thorac Oncol. 2023 Dec 28:S1556-0864(23)02432. PubMedAbstract available
ODINTSOV I, Makarem M, Nishino M, Bachert SE, et al Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in
Non-Small Cell Lung Cancer.
J Thorac Oncol. 2023 Dec 26:S1556-0864(23)02428. PubMedAbstract available
BISCHOFF P, Reck M, Overbeck T, Christopoulos P, et al Outcome of first-line treatment with pembrolizumab according to KRAS/TP53
mutational status for non-squamous PD-L1 high (>/=50%) NSCLC in the German National
Network Genomic Medicine Lung Cancer (nNGM).
J Thorac Oncol. 2023 Dec 12:S1556-0864(23)02423. PubMedAbstract available
VAN SCHIL PE, Asamura H, Nishimura KK, Rami-Porta R, et al The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T
Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung
Cancer.
J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02411. PubMedAbstract available
LI W, Fei K, Guo L, Wang Y, et al CD74/SLC34A2-ROS1 fusion variants involving the transmembrane region predict poor
response to crizotinib in non-small cell lung cancer independent of TP53
mutations.
J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02414. PubMedAbstract available
DACIC S, Travis WD, Giltnane JM, Kos F, et al Artificial intelligence-powered assessment of pathologic response to neoadjuvant
atezolizumab in patients with non-small cell lung cancer: results from the LCMC3
study.
J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02415. PubMedAbstract available
XHEMALAJ D, Gradica F, Skenduli I, Tula J, et al Lung Cancer in Albania.
J Thorac Oncol. 2023;18:1632-1637. PubMed
FERREIRA M, Redman MW, Reckamp KL Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.
J Thorac Oncol. 2023;18:1629-1631. PubMed
LI Z, Lu S Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System
Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives.
J Thorac Oncol. 2023;18:1625-1628. PubMed
MAKAREM M, Rotow JK Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy
Response.
J Thorac Oncol. 2023;18:1615-1617. PubMed
RUFFINI E, Huang J, Cilento V, Goren E, et al The International Association for the Study of Lung Cancer Thymic Epithelial
Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming
(Ninth) Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2023;18:1655-1671. PubMedAbstract available
MAROM EM, Fang W, Ruffini E, Detterbeck F, et al The International Association for the Study of Lung Cancer Thymic Epithelial
Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy
Interest Group/International Association for the Study of Lung Cancer Lymph Node
Map for Thymic
J Thorac Oncol. 2023;18:1672-1688. PubMedAbstract available
OKUMURA M, Marino M, Cilento V, Goren E, et al The International Association for the Study of Lung Cancer Thymic Epithelial
Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth)
Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2023;18:1638-1654. PubMedAbstract available
ANG YLE, Soo RA Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the
Post-Crizotinib Setting?
J Thorac Oncol. 2023;18:1621-1624. PubMed
MEDINA CG, Xu Y, Ripley RT International Prognostic Modeling: A Platform for Collaborative Approach for
Patients With Mesothelioma.
J Thorac Oncol. 2023;18:1618-1620. PubMed
SOO RA, Cho BC, Kim JH, Ahn MJ, et al Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated
Advanced NSCLC: A LASER301 Subset Analysis.
J Thorac Oncol. 2023;18:1756-1766. PubMedAbstract available
WOLF AS, Rosenthal A, Giroux DJ, Nowak AK, et al The International Association for the Study of Lung Cancer Pleural Mesothelioma
Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.
J Thorac Oncol. 2023;18:1689-1702. PubMedAbstract available
November 2023
WANG K, Du R, Myall NJ, Lewis WE, et al BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant
non-small cell lung cancer (NSCLC).
J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02376. PubMedAbstract available
O'LEARY CL, Pierce N, Patel SP, Naidoo J, et al Immune-Related Toxicity in Non-small cell Lung Cancer: Current State-of-The-Art
and Emerging Clinical Challenges.
J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02374. PubMedAbstract available
LIAO W, Fehnel C, Goss J, Shepherd CJ, et al Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer
Screening in a Mississippi Delta Cohort.
J Thorac Oncol. 2023 Nov 18:S1556-0864(23)02371. PubMedAbstract available
LU C, Wei XW, Wang Z, Zhou Z, et al Allelic context of EGFR C797X mutant lung cancer defines four subtypes with
heterogeneous genomic landscape and distinct clinical outcomes.
J Thorac Oncol. 2023 Nov 17:S1556-0864(23)02372. PubMedAbstract available
HENSCHKE C, Huber R, Jiang L, Yang D, et al Perspective on Management of LDCT Findings on Low-Dose Computed Tomography
Examinations for Lung Cancer Screening From the IASLC Early Detection & Screening
Committee.
J Thorac Oncol. 2023 Nov 16:S1556-0864(23)02369. PubMedAbstract available
GULATI S, Ivic-Pavlicic T, Joasil J, Flores R, et al Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery
Patients.
J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02364. PubMedAbstract available
CARTMEL B, Fucito LM, Bold KW, Neveu S, et al No Additional Effect of a Personalized Tobacco Treatment Intervention on Smoking
Abstinence in Individuals Eligible for Lung Cancer Screening: Brief Report of a
Randomized Trial.
J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02368. PubMedAbstract available
YANG JJ, Wen W, Zahed H, Zheng W, et al Lung Cancer Risk Prediction Models for Asian Ever-Smokers.
J Thorac Oncol. 2023 Nov 7:S1556-0864(23)02352. PubMedAbstract available
KUBO N, Suefuji H, Nakajima M, Tokumaru S, et al Five-year survival outcomes after carbon-ion radiotherapy for operable stage I
non-small cell lung cancer: a Japanese national registry study (J-CROS-LUNG).
J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02346. PubMedAbstract available
HARATAKE N, Ozawa H, Morimoto Y, Yamashita N, et al MUC1-C IS A COMMON DRIVER OF ACQUIRED OSIMERTINIB RESISTANCE IN NON-SMALL CELL
LUNG CANCER.
J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02348. PubMedAbstract available
HONG TH, Hwang S, Cho J, Choi YL, et al Clinical Significance of the Proposed Pathologic Criteria for Invasion by the
International Association for the Study of Lung Cancer in Resected Nonmucinous
Lung Adenocarcinoma.
J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02311. PubMedAbstract available
QIU Z, Huang H, Zhang Y, Chen D, et al Comment on "Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for
Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief
Report".
J Thorac Oncol. 2023;18:e138-e139. PubMed
LI A, Yang Y, Zhang L, Hong S, et al STK11/LKB1 and Immune Phenotypes Co-Determine Immunotherapy Outcomes.
J Thorac Oncol. 2023;18:e135-e138. PubMed
AMORI G, Sugawara E, Inamura K Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in
NSCLC: STK11 Deficiency and Beyond.
J Thorac Oncol. 2023;18:e134-e135. PubMed
CHEN WM, Yu YH, Chen M, Shia BC, et al Correspondence: The Causality Between Statin Use and Reduced Mortality of
Esophageal Cancer Remains Unproven.
J Thorac Oncol. 2023;18:e132-e134. PubMed
ZHANG Y, Dai K, He D, Chen Z, et al The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer
Remains Unproven.
J Thorac Oncol. 2023;18:e130-e131. PubMed
NIU Y, Yao F, Yang H "Keaping" an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung
Cancer.
J Thorac Oncol. 2023;18:e126-e128. PubMed
MARTI JLG, Wells JZ, Wells A Statins as a Secondary Preventive Agent for Metastatic Cancer.
J Thorac Oncol. 2023;18:e125-e126. PubMed
OKONTA KE, Baiyewu LA, Jimoh MA Lung Cancer in Nigeria.
J Thorac Oncol. 2023;18:1446-1457. PubMed
DAGOGO-JACK I We Don't Talk (Enough) About BRAF.
J Thorac Oncol. 2023;18:1443-1445. PubMed
LEE JB, Ou SI Plasma Genotyping From the CROWN, ALTA-1L, and ALEX Trials: Can We Speak With One
Voice on What to Test, How to Test, When to Test, and for What Purpose?
J Thorac Oncol. 2023;18:1434-1442. PubMed
HIJAZO-PECHERO S, Munoz-Pinedo C, Nadal E A Transcriptomic Approach Outperforms Mutational Analysis to Identify
KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
J Thorac Oncol. 2023;18:1431-1433. PubMed
SOZZI G, Pastorino U Small RNAs Do It Better.
J Thorac Oncol. 2023;18:1428-1430. PubMed
YANKELEVITZ DF, Yip R, Henschke CI Considerations for Incorporating Family History Into Low-dose Computed Tomography
Screening Recommendations.
J Thorac Oncol. 2023;18:1426-1427. PubMed
SAKAI T, Matsumoto S, Ueda Y, Shibata Y, et al Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF
Non-V600E Mutations: A Multi-Institutional Genomic Screening Study
(LC-SCRUM-Asia).
J Thorac Oncol. 2023;18:1538-1549. PubMedAbstract available
AHN MJ, Bondarenko I, Kalinka E, Cho BC, et al Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance
Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
J Thorac Oncol. 2023;18:1594-1606. PubMedAbstract available
October 2023
WANG L, Luo Y, Ren S, Zhang Z, et al A phase Ib study of ivonescimab, a PD-1/VEGF bispecific antibody, as first- or
second-line therapy for advanced or metastatic immunotherapy naive non-small-cell
lung cancer.
J Thorac Oncol. 2023 Oct 23:S1556-0864(23)02312. PubMedAbstract available
HUANG J, Osarogiagbon RU, Giroux DJ, Nishimura KK, et al The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N
Descriptors in the Forthcoming 9th Edition of the TNM Classification for Lung
Cancer.
J Thorac Oncol. 2023 Oct 20:S1556-0864(23)02310. PubMedAbstract available
CHO MH, Cho JH, Eun Y, Han K, et al Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study.
J Thorac Oncol. 2023 Oct 12:S1556-0864(23)02293. PubMedAbstract available
STOCKHAMMER P, Grant M, Wurtz A, Foggetti G, et al Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with
Worse Outcomes in Patients with EGFR-mutant Lung Cancer.
J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02264. PubMedAbstract available
HENSCHKE CI, Yip R, Sun Q, Li P, et al Prospective Cohort Study to Compare Long-term Lung Cancer-Specific and All-Cause
Survival of Clinical Early Stage (T1a-b; =20mm) Non-Small-Cell Lung Cancer
(NSCLC) Treated by Stereotactic Body Radiation Therapy (SBRT) and Surgery.
J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02265. PubMedAbstract available
ROTOW JK, Lee JK, Madison RW, Oxnard GR, et al Real-world genomic profile of EGFR second-site mutations and other osimertinib
resistance mechanisms, and clinical landscape of non-small cell lung cancer
(NSCLC) post-osimertinib.
J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02263. PubMedAbstract available
TRIPHURIDET N, Gao Y, Ou SI Reply to Jayaraj et al. "Clinical Validity and Conceptual Interpretation of the
Meta-Analysis on the Efficacy of LDCT Lung Cancer Screening in Never-Smokers".
J Thorac Oncol. 2023;18:e122-e123. PubMed
JAYARAJ R, Shetty S, Ilankumaran S, Merchant Y, et al Clinical Validity and Conceptual Interpretation of Low-Dose Computed Tomography
Screening in Asian Female Never-Smokers Are as Efficacious in Detecting Lung
Cancer as in Asian Male Ever-Smokers.
J Thorac Oncol. 2023;18:e118-e122. PubMed
CHOUR A, Duruisseaux M Response to Commentary on "Brief Report: Severe Sotorasib-Related Hepatotoxicity
and Non-Liver Adverse Events Associated With Sequential Anti-PD(L)1 and Sotorasib
Therapy in KRASG12C-Mutant Lung Cancer".
J Thorac Oncol. 2023;18:e114-e115. PubMed
DETTERBECK FC, Asamura H, Rami-Porta R, Rusch VW, et al The Only Constant Is Change: Introducing the International Association for the
Study of Lung Cancer Proposals for the Ninth Edition of TNM Stage Classification
of Thoracic Tumors.
J Thorac Oncol. 2023;18:1258-1260. PubMed
INAMURA K Exploiting Tumor Immune Microenvironment to Predict Response to Immunotherapy
Plus Chemotherapy in NSCLC.
J Thorac Oncol. 2023;18:e109-e110. PubMed
ADJEI AA The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in
2024.
J Thorac Oncol. 2023;18:1257. PubMed
HOE HJ, Balasubramanian A, John T LASERing FLAURAL Arrangements in Asian EGFR Subsets.
J Thorac Oncol. 2023;18:1261-1264. PubMed
REUNGWETWATTANA T, Cho BC, Lee KH, Pang YK, et al Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naive
Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in
LASER301.
J Thorac Oncol. 2023;18:1351-1361. PubMedAbstract available
PEARSALL SM, Williamson SC, Humphrey S, Hughes E, et al Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for
Vasculogenic Mimicry.
J Thorac Oncol. 2023;18:1362-1385. PubMedAbstract available
GELSOMINO F, Vitale G, Raschi E, Ardizzoni A, et al Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and
Tyrosine Kinase Inhibitors: An Emerging Clinical Issue.
J Thorac Oncol. 2023;18:e112-e113. PubMed
CHEN WM, Yu YH, Chen M, Shia BC, et al Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved
Survival Outcomes in Esophageal Squamous Cell Carcinoma.
J Thorac Oncol. 2023;18:e107-e109. PubMed
LIN TA, Chen SY, Chang R, Sun CK, et al Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved
Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity
Score-Matched Nationwide Cohort Study.
J Thorac Oncol. 2023;18:e105-e106. PubMed
WRIGHT K, Digby GC, Gyawali B, Jad R, et al Malignant Superior Vena Cava Syndrome: A Scoping Review.
J Thorac Oncol. 2023;18:1268-1276. PubMedAbstract available
September 2023
DUAN J, Wu L, Yang K, Zhao J, et al Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in
treatment-naive patients with advanced non-small cell lung cancer harboring EGFR
exon 20 insertion mutations: A phase I trial.
J Thorac Oncol. 2023 Sep 28:S1556-0864(23)02259. PubMedAbstract available
RECK M, Barlesi F, Chih-Hsin Yang J, Westeel V, et al Avelumab vs platinum-based doublet chemotherapy as first-line treatment for
patients with high-expression PD-L1+ metastatic non-small cell lung cancer:
primary analysis from the phase 3 JAVELIN Lung 100 trial.
J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02250. PubMedAbstract available
JIANG C, Zhang Y, Fu F, Deng P, et al A Shift in Paradigm: Selective Lymph Node Dissection for Minimizing Oversurgery
in Early-Stage Lung Cancer.
J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02245. PubMedAbstract available
TORASAWA M, Horinouchi H, Nomura S, Igawa S, et al Reconsidering the cutoff value for sensitive and refractory relapses in
extensive-stage small cell lung cancer in the era of immunotherapy.
J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02256. PubMedAbstract available
WANG X, Bai H, Zhang J, Wang Z, et al Genetic intra-tumour heterogeneity remodels the immune microenvironment and
induces immune evasion in brain metastasis of lung cancer.
J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01079. PubMedAbstract available
FIGUEROA PU, Marques E, Cilento VJ, Giroux DJ, et al Completeness of Resection and Long-term Survival of Patients Undergoing Resection
for Pathological T3 Non-small-cell Lung Cancer: An International Association for
the Study of Lung Cancer Analysis.
J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01078. PubMedAbstract available
ZHANG S, Liu L, Shi S, He H, et al Bidirectional association between cardiovascular disease and lung cancer in a
prospective cohort study.
J Thorac Oncol. 2023 Sep 11:S1556-0864(23)00806. PubMedAbstract available
August 2023
DACIC S, Travis W, Redman M, Saqi A, et al International Association for the Study of Lung Cancer Study of Reproducibility
in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant
Therapy.
J Thorac Oncol. 2023 Aug 3:S1556-0864(23)00685. PubMedAbstract available
LIN SH Statin Use and Chemoradiation in Esophageal Squamous Cell Carcinomas: Ready for
Prime Time?
J Thorac Oncol. 2023;18:970-971. PubMed
July 2023
RIMNER A, Ruffini E, Cilento V, Goren E, et al The International Association for the Study of Lung Cancer Thymic Epithelial
Tumors Staging Project: An Overview of the Central Database Informing Revision of
the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2023 Jul 24:S1556-0864(23)00672. PubMedAbstract available
June 2023
PIETROLUONGO E, De Placido P, Tortora M, Martinelli C, et al Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic
epithelial tumors.
J Thorac Oncol. 2023 Jun 28:S1556-0864(23)00634. PubMedAbstract available